Inferra AIResearch Tools

Inferra AI / Company / BAX

Baxter International

BAX · Health Care

Last earnings Oct 29, 2026

Key results

EPSquarter

$0.10

GAAP 3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10) adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company s focus to drive continuous improvement and sustainable growth and create shareholder value DEERFIELD, Ill.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Adjusted EPSquarter

$0.69

GAAP 3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.10) adjusted diluted EPS from continuing operations of $0.69 Andrew Hider joined the company as president and chief executive officer (CEO), now leading the company s focus to drive continuous improvement and sustainable growth and create shareholder value DEERFIELD, Ill.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Net incomequarter

$51

GAAP basis, net income (loss) from continuing operations totaled ($51) million, or ($0.10) per diluted share in the third quarter.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

On an adjusted basis, net income from continuing operations in the third quarter was $0.69 per diluted share, increasing 41% over the prior year.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Medical Products Therapies revenuequarter

$1.33 billion

Third-Quarter 2025 Segment Results Medical Products Therapies sales for the third quarter totaled approximately $1.33 billion, declining 1% on both a reported and operational basis.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

AI analysis

Q3 2025 · reported Oct 30, 2025

Based on: Earnings release + parent 8-K — transcript not held

EPS · Q3 2025
$0.10
EX-99 · Oct 30, 2025
Adjusted EPS · Q3 2025
$0.69
+187.5% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Net income · Q3 2025
$51
-100.0% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025
Medical Products Therapies revenue · Q3 2025
$1.33B
+0.8% vs prior quarter computed from stated figures
EX-99 · Oct 30, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
EPS$0.10$0.24—
Adjusted EPS$0.69$0.24—
Net income$51$122 million—
Medical Products Therapies revenue$1.33 billion$1.32 billion—

EX-99 · Oct 30, 2025

Guidance · company-stated

sales

“growth from continuing operations of 4% to 5%”

Guidance stated in the release for full-year 2025; figures as stated.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

Following this work, we have already taken decisive steps, including the launch of a new enterprise-wide continuous improvement system to sharpen execution and strengthen future results

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

sales: “sales growth from continuing operations of 4% to 5%”

sales (“full-year 2025”)
“2025 Financial Outlook For full-year 2025 Baxter now expects sales growth from continuing operations of 4% to 5% on a reported basis.”

Guidance stated in the release for full-year 2025; figures as stated.

Capital allocation

This release and the accompanying tables also include free cash flow, a non-GAAP financial measure that Baxter defines as operating cash flow less capital expenditures.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Strategy & priorities

Recent Highlights 4 Baxter continues to advance key strategic priorities in pursuit of its Mission to Save and Sustain Lives.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements the company's ability to achieve the intended benefits of its recent strategic actions, including the sale of the Kidney Care business, business strategy and development activities (including the acquisition Hill-Rom Holdings, Inc.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

These restructuring and business optimization costs in 2025 included costs primarily related to its initiatives to reduce its cost structure following the sale of its former Kidney Care segment and the exit of a product line at one of its manufacturing facilities.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

These restructuring and business optimization costs in 2024 included costs which were primarily related to its implementation of a new operating model intended to simplify and streamline its operations and better align its manufacturing and supply chain to its commercial activities and initiatives within its Healthcare Systems Technologies segment.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

These restructuring and business optimization costs in 2024 included costs related to its implementation of a new operating model intended to simplify and streamline its operations and better align its manufacturing and supply chain to its commercial activities and and initiatives within its Healthcare Systems Technologies segment.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Risks & headwinds

I ve been working side-by-side with our teams to understand what drives performance, as well as our challenges and opportunities ahead.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Baxter has not provided reconciliations of forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments and unusual gains and losses, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)( i)(B) of Regulation S-K).

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Baxter has not provided reconciliations of forward-looking adjusted EPS guidance to forward-looking GAAP EPS guidance because the company is unable to predict with reasonable certainty the impact of legal proceedings, future business optimization actions, separation-related costs, integration-related costs, asset impairments and unusual gains and losses, and the related amounts are unavailable without unreasonable efforts (as specified in the exception provided by Item 10(e)(1)(i)(B) of Regulation S-K).

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

What changed vs prior quarter

Net income — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Medical Products Therapies revenue — prior quarter passage and this quarter's passage are both cited.

SEC original ↗Baxter International — Earnings release (8-K exhibit)EX-99Oct 30, 2025

Documents

Earnings deck slides

0 decks with slide view

Baxter International — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Gilead Sciences (GILD) Health CareGenmab (GMAB) Health CareAlcon (ALC) Health CareArgenx (ARGX) Health CareSanofi (SNY) Health CareMerck & Co. (MRK) Health CareXencor Inc (XNCR) Health CareIllumina, Inc. (ILMN) Health Care

Filings

35 documents

Earnings releases

9 documents

Presentations

1 document

Transcripts

0 documents

No transcripts for Baxter International are held in this edition of the library.

Mentioned by

1 company

Other tracked companies whose held documents mention Baxter International by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.